DK2635297T3 - En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet - Google Patents

En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet Download PDF

Info

Publication number
DK2635297T3
DK2635297T3 DK11838863.6T DK11838863T DK2635297T3 DK 2635297 T3 DK2635297 T3 DK 2635297T3 DK 11838863 T DK11838863 T DK 11838863T DK 2635297 T3 DK2635297 T3 DK 2635297T3
Authority
DK
Denmark
Prior art keywords
antihemophil
specific activity
factor viii
increased specific
new variant
Prior art date
Application number
DK11838863.6T
Other languages
Danish (da)
English (en)
Inventor
Chee Kong Lai
Roddy Kevin Stafford
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of DK2635297T3 publication Critical patent/DK2635297T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK11838863.6T 2010-11-05 2011-11-04 En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet DK2635297T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (1)

Publication Number Publication Date
DK2635297T3 true DK2635297T3 (da) 2019-05-06

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11838863.6T DK2635297T3 (da) 2010-11-05 2011-11-04 En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet

Country Status (18)

Country Link
US (2) US9150637B2 (enExample)
EP (1) EP2635297B1 (enExample)
JP (1) JP5922141B2 (enExample)
KR (1) KR101948337B1 (enExample)
CN (1) CN103298483B (enExample)
AU (1) AU2011323236B2 (enExample)
BR (1) BR112013011041B1 (enExample)
CA (1) CA2816575C (enExample)
CO (1) CO6720990A2 (enExample)
DK (1) DK2635297T3 (enExample)
EA (1) EA035447B1 (enExample)
ES (1) ES2721478T3 (enExample)
IL (1) IL226158B (enExample)
MX (2) MX351220B (enExample)
MY (1) MY165089A (enExample)
SG (2) SG10201509149VA (enExample)
WO (1) WO2012061689A2 (enExample)
ZA (1) ZA201303816B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123200A1 (en) * 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
EP0710288B1 (en) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α1プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
CA2252896C (en) * 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2312291A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
ATE310533T1 (de) 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1319016A4 (en) 2000-09-19 2006-05-10 Univ Emory MODIFIED FACTOR VIII
ATE417618T1 (de) * 2001-10-05 2009-01-15 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
MXPA04005079A (es) 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
WO2009075772A1 (en) 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof

Also Published As

Publication number Publication date
CN103298483B (zh) 2017-04-12
EP2635297A2 (en) 2013-09-11
EP2635297A4 (en) 2014-06-25
EA201390654A1 (ru) 2014-01-30
MX2013005047A (es) 2013-12-06
US20130296244A1 (en) 2013-11-07
KR20140114266A (ko) 2014-09-26
EA035447B1 (ru) 2020-06-17
JP2013545459A (ja) 2013-12-26
ZA201303816B (en) 2021-05-26
CN103298483A (zh) 2013-09-11
SG190136A1 (en) 2013-07-31
US10053500B2 (en) 2018-08-21
AU2011323236A8 (en) 2013-07-25
WO2012061689A3 (en) 2012-10-04
KR101948337B1 (ko) 2019-02-14
AU2011323236A1 (en) 2013-06-06
AU2011323236B2 (en) 2017-03-30
US9150637B2 (en) 2015-10-06
CA2816575C (en) 2019-06-11
SG10201509149VA (en) 2015-12-30
MX351220B (es) 2017-10-05
IL226158B (en) 2019-08-29
ES2721478T3 (es) 2019-07-31
JP5922141B2 (ja) 2016-05-24
BR112013011041B1 (pt) 2021-05-25
CA2816575A1 (en) 2012-05-10
MY165089A (en) 2018-02-28
US20150353625A1 (en) 2015-12-10
WO2012061689A2 (en) 2012-05-10
IL226158A0 (en) 2013-06-27
BR112013011041A2 (pt) 2017-06-06
EP2635297B1 (en) 2019-02-27
MX347503B (es) 2017-04-26
CO6720990A2 (es) 2013-07-31

Similar Documents

Publication Publication Date Title
NL300958I2 (nl) Rucaparib camsylaat
BR112013030533A2 (pt) catalisadores
EP2764065A4 (en) VICTIMS ADHESIVE LAYERS
DK3473714T3 (da) Polypeptider, der har transgalactosyleringsaktivitet
DK3269802T3 (da) Forbindelser til forbedret virustransduktion
FI20115151A7 (fi) Uudet mikromekaaniset laitteet
BR112014001438A2 (pt) distribuidor nômade recarregável
EP2679338A4 (en) Machining center
PT2665662T (pt) Cabeça de pulverização
EP2664324A4 (en) NANO CAPSULES WITH A POLYMER CASE
EP2634546A4 (en) BALANCE OF COMBINATION
FI20115811L (fi) Puomisto
EP2855013A4 (en) REGENERATION OF CATALYSTS FOR HYDROGENATION OF SUGAR
DK2532220T3 (da) Marksprøjte
FI20115336A7 (fi) Suihkutuspää
BR112015014228A2 (pt) nanocápsulas de protamina
BR112013011936A2 (pt) deca-hidro -1, 4-metanonaftaleno - carboxamidas
BR112013028495A2 (pt) catalisadores
SMT201400109B (it) Composto cicloesanico
EP2752241A4 (en) CATALYST
DK2478758T3 (da) Fordelermaskine
BR112013032165A2 (pt) catalisadores
FI20105909A0 (fi) Suutinpää
EP2720530A4 (en) Outrigger
FR2964941B1 (fr) Pale a vulnerabilite minimisee